The version of Figure 3C that appeared in this issue was incorrect. The following figure should have appeared.

thumbnail image

Figure 3. Complete radiographic response of metastatic base of tongue squamous cell carcinoma after concurrent sunitinib and image-guided radiotherapy. A patient with a history of base of tongue cancer was treated with surgery and postoperative radiation 6 years ago. He represented 6 months ago with otalgia and was diagnosed with a T3N0M0 recurrence in the base of tongue treated with salvage surgery. He was noted on follow-up PET/CT to have a solitary enlarged subcarinal lymph node measuring 5.5 cm. Fine needle aspiration was positive for metastatic squamous cell carcinoma. (a) Pretreatment CT of the chest demonstrates a bulky subcarinal lymph node. Note fiducial marker placed for image-guided radiation therapy. The patient received 50 Gy with 37.5 mg of sunitinib as part of the expanded cohort of dose level 3. Care was taken to limit the maximum esophagus dose to 40 Gy with IMRT planning, particularly in the region of tumor bulk where no esophageal lumen could be identified. (b) To optimize therapeutic ratio of a tumor immediately adjacent to a critical structure, a simultaneous integrated boost IMRT plan was generated to deliver 4 Gy to the entire target volume while administering 5 Gy to the portion of the tumor that does not abut the esophagus. The maximum esophagus dose is limited to 4 Gy. He tolerated treatment well save for transient cough, grade 3 lymphopenia, and fatigue. (c) Posttreatment CT at 3 months after radiation demonstrated complete resolution of the large subcarinal mass and interval resolution of the subcarinal mass. The esophageal lumen is now visible and a small air collection measuring 1 cm of uncertain etiology is now present. There is no significant PET activity in this region (not shown).

Download figure to PowerPoint

The authors regret this error.